Cargando…
Epigenetic remodelling in human hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer, being the sixth most commonly diagnosed cancer and the fourth leading cause of cancer-related death. As other heterogeneous solid tumours, HCC results from a unique synergistic combination of genetic alterations mixed with epi...
Autores principales: | Braghini, Maria Rita, Lo Re, Oriana, Romito, Ilaria, Fernandez-Barrena, Maite G., Barbaro, Barbara, Pomella, Silvia, Rota, Rossella, Vinciguerra, Manlio, Avila, Matias A., Alisi, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943959/ https://www.ncbi.nlm.nih.gov/pubmed/35331312 http://dx.doi.org/10.1186/s13046-022-02297-2 |
Ejemplares similares
-
Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
por: Romito, Ilaria, et al.
Publicado: (2021) -
Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
por: Romito, Ilaria, et al.
Publicado: (2022) -
New Insights on the Nuclear Functions and Targeting of FAK in Cancer
por: Pomella, Silvia, et al.
Publicado: (2022) -
FAK Signaling in Rhabdomyosarcoma
por: Perrone, Clara, et al.
Publicado: (2020) -
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg
por: Fernández-Barrena, Maite G., et al.
Publicado: (2020)